Skip to content

PNC-27

Also called p53-derived anticancer research peptide

Peptide combining a p53 HDM-2-binding domain with a membrane-resident domain.

  • TypePeptide
  • FormInjectable
  • Researched forLongevity

Where to get PNC-27

Biolongevity Labs
Injectable
Code CAMERON

The only form sold. Research compound, not approved for human use.

Shop injectable at Biolongevity Labs

The short version

  • Why people research itMitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
  • What the evidence isNo human trials: development stopped at preclinical, so the ceiling on any claim here is a rodent model — and these transfer poorly.
  • What to watchFever with shaking chills.

How PNC-27 works

Peptide combining a p53 HDM-2-binding domain with a membrane-resident domain — researched for selectively forming pores in cancer-cell membranes while sparing normal cells.

PNC-27 is two peptides stitched end to end, and the whole molecule only makes sense once you know which half does what. The front half is residues 12–26 of human p53 — the stretch of the p53 transactivation domain that binds HDM-2, the human double minute 2 protein.

The mechanism is not the one the name suggests. HDM-2 is famous as the ubiquitin ligase that degrades p53, and the obvious guess is that a p53 fragment blocks that interaction and restores p53. That is not what this peptide does.

  • Injectable

Research on PNC-276 evidence notes: clinical, correlative, mechanism

Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work

Evidence on file: In-vitro + animal (oncology research).

Human clinical evidence

  • No human trials: development stopped at preclinical, so the ceiling on any claim here is a rodent model — and these transfer poorly.

    No completed human trial

Correlative data

  • This is the compound in the Vault most likely to be encountered by someone who is frightened and looking for options, and the honest position needs stating plainly: there are no human trials, and no clinical evidence of benefit in any cancer.

  • It is sold in the research market with claims that outrun the data by a wide margin. Choosing it over evaluated oncology care is where the real harm sits.

How the mechanism reads

  • A peptide combining a p53 fragment with a membrane-penetrating sequence. Cell work reports it binds HDM-2 in the membranes of cancer cells and forms pores, causing necrosis — while sparing normal cells, which are said to express far less membrane HDM-2.

    Mechanistic
  • The selectivity claim is the entire premise and it rests on cell culture. Selectivity that holds in a dish routinely fails in a body, where distribution, protein binding and clearance all intervene.

    Experimental, animal or cell
  • A pore-forming mechanism predicts its own risk: if the selectivity is imperfect in vivo, the damage is membrane lysis in whatever tissue it reaches.

    Mechanistic

Sources

  • Sarafraz-Yazdi E, et al. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proceedings of the National Academy of Sciences 2010 · PMID 20080680
  • Sarafraz-Yazdi E, et al. PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis. Biomedicines 2022 · PMID 35625682
  • Krzesaj P, et al. Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption. Annals of Clinical and Laboratory Science 2024 · PMID 38802154
  • Pincus MR, et al. Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells. Biomedicines 2024 · PMID 38927351
  • Thadi A, et al. Anti-Cancer Tumor Cell Necrosis of Epithelial Ovarian Cancer Cell Lines Depends on High Expression of HDM-2 Protein in Their Membranes. Annals of Clinical and Laboratory Science 2020 · PMID 33067207
  • Davitt K, et al. The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells. Annals of Clinical and Laboratory Science 2014 · PMID 25117093

PNC-27 safety basicsWho should avoid it, what to expect, what to watch

Avoid if

  • A cancer diagnosis in which you plan to use it in place of established treatment.
  • Kidney or liver failure: pore-forming activity against membranes in organs that clear drugs is untested.
  • Needing an unsterile or unverified source for an intravenous route.
  • Pregnancy: membrane-disrupting peptides carry no safety data.
  • Active infection or immune suppression.

What’s expected

  • Human effects are unknown; evidence is test-tube and animal only.
  • Fever, chills or fatigue if it provokes an immune or lytic reaction.
  • Local soreness where it is applied.

Watch for

  • Fever with shaking chills.
  • Hives, throat tightness or low blood pressure.
  • Passing little or dark urine.
  • Unexplained bleeding or bruising.

Labs that tell you it’s working

  • Complete Blood Count (CBC) w/ Differential
  • Comprehensive Metabolic Panel (CMP)
  • Cystatin C with eGFR
  • hs-CRP (C-Reactive Protein, High Sensitivity)

A p53 HDM-2 binding domain joined to a membrane-pore domain, researched for pores in cancer cells; no human results. PMID 20080680 PMID 25117093

Bloodwork to runHow you would know it is working: 8 tests in one order, code CAMERON

PNC-27 FAQ4 common questions

Is PNC-27 approved for human use?
No. PNC-27 is a research compound. No completed randomized human trial has given it yet.
What is PNC-27 researched for?
Mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Which labs show whether it's doing anything?
Complete Blood Count; Comprehensive Metabolic Panel; Cystatin C with eGFR; hs-CRP: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
Where's the full protocol?
In the Skool lesson for PNC-27: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.
The Before-You-Stack Lab Kit cover

The free Before‑You‑Stack Lab Kit

The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.

After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.

Protocol & dosing: inside Skool

This page covers what PNC-27 is. Skool covers how it is run.

Free on this page

What PNC-27 is and how it works · The research, labeled by the kind of evidence · Its own safety lines and the bloodwork panel

  • What PNC-27 is and how it works
  • The research, labeled by the kind of evidence
  • Its own safety lines and the bloodwork panel

Members get

  • The reported research range, and how each number was reached
  • The protocols: what to run together, in what order, for how long and when to stop
  • The members' prep tool, and live Q&A with Cam every Tuesday
Join Skool $10/mo1,500+ members, 5.0 rating from 15 reviews. Cancel anytime.
The members' Prep Bench in Skool: the compound finder (no dose shown)
The members’ Prep Bench

Want it built around you?

The coaching app, with sample data

1-on-1 coaching with Cam

Your plan, your bloodwork and your check-ins, built around you.

Research Protocol $150/mo · Full Coaching $250/mo

See coaching

One question? Book a 15-minute consult

A call with Cam on the one thing you are stuck on.

$75 per call

Book a consult

Educational and research purposes only. Not medical advice. Research compounds are discussed for research use only, not human use. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer & affiliate disclosure

Buy with codeJoin Skool